...
首页> 外文期刊>Homeopathy: the journal of the Faculty of Homeopathy >Efficacy of homeopathic intervention in subclinical hypothyroidism with or without autoimmune thyroiditis in children: An exploratory randomized control study
【24h】

Efficacy of homeopathic intervention in subclinical hypothyroidism with or without autoimmune thyroiditis in children: An exploratory randomized control study

机译:顺势疗法对亚临床甲状腺功能减退症伴或不伴自身免疫性甲状腺炎的儿童的疗效:一项探索性随机对照研究

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Introduction: The decision to treat subclinical hypothyroidism (SCH) with or without autoimmune thyroiditis (AIT) in children, presents a clinical dilemma. This study was undertaken to evaluate the efficacy of individualized homeopathy in these cases. Methods: The study is an exploratory, randomized, placebo controlled, single blind trial. Out of 5059 school children (06-18 years) screened for thyroid disorders, 537 children had SCH/AIT and 194 consented to participate. Based on primary outcome measures (TSH and/or antiTPOab) three major groups were formed: Group A - SCH+AIT (. n=38; high TSH with antiTPOab+), Group B - AIT (. n=47; normal TSH with antiTPOab+) and Group C - SCH (. n=109; only high TSH) and were further randomized to two subgroups-verum and control. Individualized homeopathy or identical placebo was given to respective subgroup. 162 patients completed 18 months of study. Results: Baseline characteristics were similar in all the subgroups. The post treatment serum TSH (Group A and C) returned to normal limits in 85.94% of verum and 64.29% of controls (. p<0.006), while serum AntiTPOab titers (Group A and B) returned within normal limits in 70.27%of verum and 27.02%controls (. p<0.05). Eight children (10.5%) progressed to overt hypothyroidism (OH) from control group. Conclusion: A statistically significant decline in serum TSH values and antiTPOab titers indicates that the homeopathic intervention has not only the potential to treat SCH with or without antiTPOab but may also prevent progression to OH.
机译:简介:决定在儿童中是否伴有自身免疫性甲状腺炎(AIT)的亚临床甲状腺功能减退症(SCH)的治疗提出了临床难题。进行这项研究以评估在这些情况下个体化顺势疗法的疗效。方法:该研究是一项探索性,随机,安慰剂对照,单盲试验。在筛查甲状腺疾病的5059名学龄儿童(06-18岁)中,有537名患有SCH / AIT的儿童和194名同意参加。根据主要结局指标(TSH和/或抗TPOab),分为三个主要组:A组-SCH + AIT(。n = 38;抗TPOab +的高TSH),B组-AIT(。n = 47;抗TPOab +的正常TSH )和C组-SCH(.n = 109;仅高TSH),并进一步随机分为两个小组-普通和对照组。个体化的顺势疗法或相同的安慰剂被给予各自的亚组。 162名患者完成了18个月的研究。结果:所有亚组的基线特征相似。治疗后血清TSH(A组和C组)在正常值的85.94%和对照组的64.29%(。p <0.006)中恢复正常水平,而血清抗TPOab滴度(A组和B组)在正常值的70.27%内恢复正常Verum和27.02%的对照(。p <0.05)。对照组有8名儿童(占10.5%)发展为明显的甲状腺功能减退症(OH)。结论:血清TSH值和抗TPOab滴度的统计学显着下降表明,顺势疗法不仅具有治疗伴有或不伴有抗TPOab的SCH的潜力,而且还可以防止进展为OH。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号